Q2 FY2026 EarningsQ2 FY26 results for Artiva Biotherapeutics (ARTV.US) were largely in-line with consensus on a bottom-line basis, reporting a GAAP EPS of -$0.63 vs. the -$0.625 expected. The company remains in a pre-revenue stage ($0 actual vs. $0 consensus) as it focuses on clinical development. A significant $300M underwritten offering in May 2026 has fortified the balance sheet to $349.4M, extending the cash runway into 2029. The clinical pipeline remains the primary value driver, with a Phase 3 trial for AlloNK in refractory RA scheduled to initiate in H2 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Artiva Biotherapeutics(ARTV) the EBIT is -26.89 M (-17.89%), Miss estimate;the EPS is -0.63 (+27.59%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.03B17.89%
-0.03B12.11%
-0.00B5.78%
EPSMiss expectations
-0.6327.59%
-0.62528.16%
-0.00500.57%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf